SMO and medulloblastoma: The use of SMO inhibitors has been associated with the acquisition of resistance to SMO inhibitors, mostly described in medulloblastoma, as a consequence of (i) mutations in human SMO (D473H) and the matching mutation in mouse (D477G), observed during vismodegib treatment (Ref.